1,5-Anhydro-D-Mannitol Is a Potentially Low-Energy Carbohydrate: A Dual-Model Approach in Rats and a Randomized, Three-Way Crossover Trial in Humans.
Kenichi Tanabe, Ikuma Tanaka, Hiromi Hayashi, Kazuhiro Yoshinaga, Sadako Nakamura · Nutrients · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 15 healthy young participants, after ingestion of 5 g AM in humans, the 14 h area under the curve for breath hydrogen excretion was markedly lower after AM than that after FOS ingestion (p < 0.05). These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 15 healthy young participants. After ingestion of 5 g AM in humans, the 14 h area under the curve for breath hydrogen excretion was markedly lower after AM than that after FOS ingestion (p < 0.05).
What the Researchers Studied
The researchers studied 15 healthy young participants. The study used a randomized, crossover human clinical trial. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Extracorporeal hydrogen gas: Following AM, FOS, or ERT administration, each rat was placed in an individual circulatory metabolic measurement apparatus (Sugiyamagen-Iriki Co., Ltd., Tokyo, Japan). Extracorporeal hydrogen gas analysis: Extracorporeal hydrogen gas concentration was determined with a gas chromatograph–based H₂ /CH 4 Breath Gas Analyzer BGA-1000D (Laboratory for Expiration Biochemistry Nourishment Metabolism, Nara, Japan). Outcomes: The primary outcome was breath hydrogen output. After ingestion of 5 g AM in humans, the 14 h area under the curve for breath hydrogen excretion was markedly lower after AM than that after FOS ingestion (p < 0.05). The authors concluded that these findings indicate that AM is potentially a low-energy carbohydrate.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, crossover human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 15 healthy young participants. The reported sample size was 15. The study used a randomized, crossover human clinical trial.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.